Maxim Group Reiterates $14.00 Price Target for Galmed Pharmaceuticals (NASDAQ:GLMD)
Galmed Pharmaceuticals (NASDAQ:GLMD) has been given a $14.00 price target by equities researchers at Maxim Group in a research report issued on Wednesday, January 3rd. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 36.45% from the company’s previous close.
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. Zacks Investment Research lowered shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Roth Capital assumed coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, Seaport Global Securities restated a “buy” rating and issued a $19.00 target price on shares of Galmed Pharmaceuticals in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.20.
Shares of Galmed Pharmaceuticals (GLMD) opened at $10.26 on Wednesday. Galmed Pharmaceuticals has a 12 month low of $3.90 and a 12 month high of $12.22. The stock has a market cap of $154.74, a price-to-earnings ratio of -8.41 and a beta of 2.46.
A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. purchased a new stake in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned approximately 0.15% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 9.80% of the stock is currently owned by institutional investors.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.